Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ERADICATE: Elacestrant Plus Trastuzumab Deruxtecan in HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer
NCT07198724Phase 2Recruiting
- Start
- Nov 2025
- Primary completion
- Jun 2028
- Modality
- Molecular Glues
- Countries
- 1
01
Overview
A Phase 2 trial of elacestrant in breast cancer. Started Nov 2025; status: recruiting.
02
Drugs
elacestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07198724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07198724.